This randomized controlled trial will evaluate the effectiveness of neuroplasticity-targeted supplements on neuroinflammatory markers and ADHD symptoms in children aged 6 to 12 years diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Participants will be randomly assigned to one of four groups: gut-targeted supplements (prebiotics and probiotics), brain-targeted supplements (omega-3 fatty acids and vitamin B1), combined supplementation, or placebo. The intervention period will last 12 weeks. Primary outcomes include changes in ADHD symptom severity and clinical scores using validated rating scales. Secondary outcomes include changes in biomarkers of neuroinflammation and neuroplasticity, including IL-6, TNF-alpha, BDNF, short-chain fatty acids, and Claudin-5.
DSM-5 confirmed ADHD diagnosis
Age 6-12 years
Medication-free or on stable stimulant medication (≥1 month)
Antibiotic use in last 4 weeks
Gastrointestinal disorders
Neurological comorbidities (e.g., epilepsy)
Severe food allergies
Khyber Medical University Peshawar
Lead sponsor
Khyber Teaching Hospital
Collaborator